-
Innovation Ranking
NewInnovation Ranking – Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia,...
-
Company Insights
Innovation and Patenting activity of Santen Pharmaceutical Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Santen Pharmaceutical Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sepetaprost in Ocular Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sepetaprost in Ocular Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sepetaprost in Ocular Hypertension Drug Details: Sepetaprost (DE-126) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sepetaprost in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sepetaprost in Open-Angle Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sepetaprost in Open-Angle Glaucoma Drug Details: Sepetaprost (DE-126) is under development for...
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glaucoma Clinical Trial Report Overview A total of 1,696 glaucoma clinical trials were conducted as of January 2024. The glaucoma clinical trial report provides a comprehensive understanding of the glaucoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-036C in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-036C...
-
Sector Analysis
Glaucoma Surgery Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Glaucoma Surgery Devices Market Report Overview The glaucoma surgery devices market size was $373.2 million in 2023. The market is expected to grow at a CAGR of more than 5% during 2023-2033. Glaucoma surgery devices are used to augment normal physiologic aqueous outflow pathways to provide effective intra-ocular pressure. Glaucoma drainage devices are designed to divert aqueous humor from the anterior chamber to an external reservoir, where a fibrous capsule forms about 4-6 weeks after surgery and regulates flow. Glaucoma...
-
Product Insights
Meibomian Blepharitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Meibomian Blepharitis - Drugs In Development, 2023’, provides an overview of the Meibomian Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meibomian Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Blepharitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Blepharitis - Drugs In Development, 2023’, provides an overview of the Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Presbyopia – Drugs In Development, 2023
Global Markets Direct’s, ‘Presbyopia - Drugs In Development, 2023’, provides an overview of the Presbyopia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...